What's Happening?
Chiesi Group, an Italian biopharmaceutical company, has finalized its acquisition of KalVista Pharmaceuticals for approximately $1.9 billion. The deal, announced on April 29, 2026, and approved by both companies' boards, involved Chiesi purchasing all
outstanding shares of KalVista at $27.00 per share in cash, representing a 36% premium over KalVista's 30-day volume-weighted average share price prior to the announcement. The acquisition was completed on June 11, 2026, with Chiesi acquiring 77.8% of KalVista's outstanding shares through a tender offer, followed by a merger of a wholly owned subsidiary with KalVista. As a result, KalVista's common stock has ceased trading on the Nasdaq Global Market. This acquisition marks Chiesi's largest deal to date and brings KalVista's oral, on-demand treatment for hereditary angioedema (HAE) into Chiesi's portfolio.
Why It's Important?
The acquisition is significant as it enhances Chiesi Group's presence in the rare disease sector, particularly in the field of rare immunology. By acquiring KalVista, Chiesi gains access to a proven drug discovery and development platform, which aligns with its strategy to address unmet medical needs in rare diseases. The deal is expected to expand Chiesi's capabilities in delivering innovative treatments to patients globally. For KalVista, the acquisition provides a substantial cash premium to its shareholders and aligns with its long-term commitment to advancing treatments for rare diseases. The integration of KalVista's treatment for HAE into Chiesi's portfolio is anticipated to improve disease management and patient outcomes, addressing significant unmet needs in the HAE community.
What's Next?
Following the acquisition, Chiesi plans to focus on integrating KalVista's operations and working closely with the HAE and scientific communities to enhance disease management. The company aims to leverage its global infrastructure and commercial capabilities to expand access to KalVista's treatment for HAE, sebetralstat, worldwide. Chiesi's commitment to rare diseases and its operational excellence are expected to facilitate the successful integration of KalVista's assets and the delivery of innovative treatments to a broader patient population.
